Mike Dixon joined Transformation Capital in 2019 after more than a decade as a partner at Sequoia Capital.
Mike currently serves on the boards of Datavant, Plushcare, and Cleo, and is involved with Transformation’s investments in Olive and H1 Insights. Previously, he served on the boards of Health Catalyst (ticker: HCAT), Clover Health (ticker: CLOV), Implantable Provider Group (acquired by TPG Growth), Trialspark, Cortexyme (observer position, ticker: CRTX), Airstrip Technologies, Endochoice (acquired by Boston Scientific), and Percolate, a marketing software-as-a-service company (acquired by Seismic). He also led or co-led additional healthcare investments in MedExpress (acquired by UnitedHealth Group), Stemcentrx (acquired by Abbvie), 23andMe, and BridgeBio (ticker: BBIO).
Prior to his time at Sequoia Capital, Mike was an Equity Research Associate at Fidelity Management & Research Company. He graduated summa cum laude from Boston College in 2006 and was a member of the Presidential Scholars Program. He lives in San Francisco with his wife and four boys.